Navigation Links
Mayo Clinic researchers building melanoma vaccine to combat skin cancer
Date:3/19/2012

ROCHESTER, Minn. -- Mayo Clinic researchers have trained mouse immune systems to eradicate skin cancer from within, using a genetic combination of human DNA from melanoma cells and a cousin of the rabies virus. The strategy, called cancer immunotherapy, uses a genetically engineered version of the vesicular stomatitis virus to deliver a broad spectrum of genes derived from melanoma cancer cells directly into tumors. In early studies, 60 percent of tumor-burdened mice were cured in fewer than three months and with minimal side effects. Results of the latest study appear this week in the journal Nature Biotechnology.

"We believe that this new technique will help us to identify a whole new set of genes that encode antigens that are important in stimulating the immune system to reject cancer. In particular, we have seen that several proteins need to be expressed together to generate the most effective rejection of the tumors in mice," says Richard Vile, Ph.D., a Mayo Clinic researcher in the Department of Molecular Medicine and a coauthor of the study, along with Jose Pulido, M.D., a Mayo Clinic ophthalmologist and ocular oncologist.

Dr. Vile's success with melanoma adds to Mayo Clinic's growing portfolio of experimental cancer vaccines, which includes an active clinical trial of vesicular stomatitis vaccines for liver cancers. Future studies could include similar vaccines for more aggressive cancers, such as lung, brain and pancreatic.

"I do believe we can create vaccines that will knock them off one by one," Dr. Vile says. "By vaccinating against multiple proteins at once, we hope that we will be able to treat both the primary tumor and also protect against recurrence."

The immune system functions on a seek-and-destroy platform and has fine-tuned its capacity to identify viral invaders such as vesicular stomatitis virus. Part of the appeal of building cancer vaccines from the whole spectrum of tumor DNA is that tumors can adapt to the repeated attacks of a healthy immune system and display fewer antigens (or signposts) that the immune system can identify.

Cancers can learn to hide from a normal immune system, but appear unable to escape an immune system trained by the vesicular stomatitis virus with the wide range of DNA used in the library approach.

"Nobody knows how many antigens the immune system can really see on tumor cells," says Dr. Vile. "By expressing all of these proteins in highly immunogenic viruses, we increased their visibility to the immune system. The immune system now thinks it is being invaded by the viruses, which are expressing cancer-related antigens that should be eliminated."

Much immunotherapy research has slowed because of researchers' inability to isolate a sufficiently diverse collection of antigens in tumor cells. Tumors in these scenarios are able to mutate and reestablish themselves in spite of the body's immune system.

The study was a Mayo collaboration with professors Alan Melcher and Peter Selby at the Leeds Institute of Molecular Medicine, University of Leeds, U.K. They were also co-authors.


'/>"/>

Contact: Robert Nellis
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. The West Clinic Joins Cancer Clinics of Excellence (CCE)
2. Stethoscope App gives iPhone New Clinical Skills
3. Mayo Clinic responsible for $22 billion in economic impact, including $9.6 billion in Minnesota
4. Sunquest Introduces Integrated Clinical Environment Physician Portal Solution in US
5. Almac Launches New STEMS System to Transform Temperature Controlled Shipment Monitoring in Clinical Trials
6. Clinical trial underway: Miniature ultrasound device could revolutionize pain relief
7. Sunquest Completes System-Wide Implementation at Cleveland Clinic Hospital Laboratories
8. Michael J. Fox Foundation Awards $1.1 Million For Clinical Trial of Transdermal Nicotine as Disease-Modifying Treatment For Parkinsons
9. NOVAVAX Presents Positive Clinical Results at The World Health Organization Conference, Geneva, Switzerland
10. UCLA Health System Presents: How to Successfully Implement a Clinical Portal
11. International Merchant Advisors CEO Mel Roseman to Discuss New Medical Marijuana Clinics Live on CBS Radio Networks Big Biz Show February 22, 2010 at 1:40 pm PST
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... ... , ... ChenMed , a leading provider of value-based care for seniors, ... as Richmond Chief Medical Officer. Dr. McCarter, formerly Associate Professor of Family Medicine ... Ambulatory Services for the UVA Health System, brings 30 years of highly relevant experience ...
(Date:7/20/2017)... (PRWEB) , ... July 20, 2017 , ... ... a telemedicine platform, in which their iMedSecure™ comes included with each system installation. ... encrypted live images to remote participants for real-time collaboration and immediate decision-making requirements. ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... FDAnews Webinar**, Aug. 9, 2017 — 1:30 p.m. – 3:00 p.m. ET, ... inspections and boosting quality. , It’s known as the “CY2016 Annual FDA Medical ...
(Date:7/20/2017)... , ... July 20, 2017 , ... ... protection services since 2014, top travel insurance solution company VisitorsCoverage Inc. has launched ... sell all major international travel insurance products online, under their own brand. The ...
(Date:7/20/2017)... ... 19, 2017 , ... At Creekwood Dental Arts, Drs. Donna G. Miller and ... dental implants in Waco, TX, using the latest dental technology for digital ... they can capture details in the oral cavity for accurate diagnoses and customized care ...
Breaking Medicine News(10 mins):
(Date:7/5/2017)... MINNEAPOLIS , July 5, 2017 Pace Analytical, a company of ... announcing today that they have acquired ESC Lab Sciences, further solidifying their position ... the United States . ... Steve Vanderboom- President and CEO of Pace Analytical ... of ESC Lab Sciences out of Mt Juliet, TN , ...
(Date:6/30/2017)... , June 30, 2017  AVACEN Medical (AVACEN) announced the ... The research describes the use of its AVACEN Treatment Method ... suffering from fibromyalgia. ... AVACEN Medical ... characterized by chronic widespread pain. It affects approximately 200 to 400 million ...
(Date:6/20/2017)... HILLS, Calif. , June 20, 2017 SkylineDx ... the use of MMprofiler with SKY92, the company,s prognostic ... In a poster presentation at the 22 nd ... Madrid, Spain , SkylineDx researchers will demonstrate ... patients. In a separate e-poster presentation ...
Breaking Medicine Technology: